|
BMS-986504 Clinical Trials
8 actively recruiting trials across 4 locations
No change since May 2026
Also known as: MRTX1719, Navlimetostat
Pipeline
Early 1: 1Phase 1: 3Phase 2: 2Phase 2/3: 2
Top Sponsors
- Bristol-Myers Squibb5
- Nader Sanai1
- Memorial Sloan Kettering Cancer Center1
- M.D. Anderson Cancer Center1
Indications
- Cancer8
- Lung Cancer2
- Gastroesophageal Carcinoma1
- Diffuse Pleural Mesothelioma1
- MTAP-deleted Pancreatic Cancer1
Other2 trials
Anchorage, Alaska2 trials
Phoenix, Arizona2 trials
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Mayo Clinic in Arizona - Phoenix
Phase 2/3
Clinical Trial of BMS-986504 in Recurrent GBM Patients
St. Joseph's Hospital and Medical Center
Early 1
Basking Ridge, New Jersey1 trial
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Phase 1
Houston, Texas1 trial
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
MD Anderson Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.